Emerald Advisers LLC Raises Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

Emerald Advisers LLC raised its stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 12.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 822,377 shares of the medical device company's stock after acquiring an additional 89,717 shares during the period. Emerald Advisers LLC owned approximately 2.15% of Orthofix Medical worth $14,359,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Franklin Resources Inc. boosted its position in shares of Orthofix Medical by 37.4% during the 3rd quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company's stock worth $337,000 after purchasing an additional 5,702 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Orthofix Medical by 14.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company's stock worth $5,073,000 after purchasing an additional 39,901 shares in the last quarter. Barclays PLC grew its stake in shares of Orthofix Medical by 38.8% in the third quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock valued at $1,912,000 after buying an additional 34,210 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Orthofix Medical by 114.9% in the 3rd quarter. HighTower Advisors LLC now owns 89,183 shares of the medical device company's stock valued at $1,393,000 after buying an additional 47,680 shares during the period. Finally, Kirr Marbach & Co. LLC IN acquired a new position in Orthofix Medical during the 4th quarter worth about $532,000. 89.76% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Roth Mkm reaffirmed a "buy" rating and issued a $22.00 target price on shares of Orthofix Medical in a research report on Wednesday, February 26th. StockNews.com raised shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $24.00 price target on shares of Orthofix Medical in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Orthofix Medical currently has a consensus rating of "Moderate Buy" and an average price target of $23.33.

Orthofix Medical Stock Down 0.7 %

Orthofix Medical stock traded down $0.12 during trading on Thursday, reaching $16.16. The stock had a trading volume of 141,486 shares, compared to its average volume of 253,965. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25. Orthofix Medical Inc. has a 52-week low of $12.08 and a 52-week high of $20.73. The stock has a market cap of $630.60 million, a PE ratio of -5.16 and a beta of 1.06. The business has a 50 day moving average price of $17.67 and a 200 day moving average price of $17.36.

Insider Buying and Selling

In other news, insider Lucas Vitale sold 4,287 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total transaction of $71,164.20. Following the completion of the transaction, the insider now directly owns 135,317 shares of the company's stock, valued at approximately $2,246,262.20. This represents a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Julie Andrews sold 4,655 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the transaction, the chief financial officer now owns 28,312 shares in the company, valued at approximately $506,501.68. The trade was a 14.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,999 shares of company stock worth $512,497. Corporate insiders own 2.60% of the company's stock.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.